All In Biotech

Drug Trial Radar · NCT04516096

A Compassionate Use Protocol of AMX0035 for Treatment of Patients With Amyotrophic Lateral Sclerosis (ALS)

AMX0035 for Amyotrophic Lateral Sclerosis - Compassionate Use Protocol

Last checked: Nov 19, 2026Latest source record: Apr 7, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

28

Actual

Start

Nov 22, 2020

Primary completion

Dec 30, 2022

Study completion Jan 31, 2023

Sponsor

Lead sponsor
Amylyx Pharmaceuticals Inc.Industry
Sponsor type
Industry
First posted
Aug 18, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2 / Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The protocol is intended to provide extended treatment with AMX0035 to patients who previously participated in an Amylyx sponsored study of AMX0035 for ALS.

Conditions

  • Amyotrophic Lateral Sclerosis

Interventions

  • AMX0035Drug

    Tauroursodeoxycholic Acid and Sodium Phenylbutyrate orally given twice a day

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Treatment emergent Adverse EventsTime frame: Through study completion an average of 1 year

Locations

5 sites in 1 country. Site status is shown where the registry gives one.

  • Forbes Norris MDA/ALS Research Center - California Pacific Medical Center

    San Francisco, California

  • Massachusetts General Hospital

    Boston, Massachusetts

  • University of Massachusetts Memorial Medical Center

    Worcester, Massachusetts

  • University of Michigan Medical Center

    Ann Arbor, Michigan

  • Wake Forest Baptist Medical Center

    Winston-Salem, North Carolina

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.